Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Clinical trial NCT04118868 · UNKNOWN
Trial details
- NCT number
- NCT04118868
- Sponsor
- Sorrento Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-31
- Primary completion
- 2024-01-29
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.